Correlation study of serum asprosin levels with renal function and glucose metabolism indexes in patients with diabetic nephropathy.

doi:10.3877/cma.j.issn.2095-9605.2021.02.007

Abstract

Abstract:

Objective

To investigate the level of serum asprosin, renal function and glucose metabolism indexes and clinical significance in patients with diabetic nephropathy (DKD).

Methods

A total of 84 patients with type 2 diabetes (T2DM) who were treated in Huizhou Central People's Hospital from January 2020 to February 2021 were selected, a total of 43 patients were diagnosed with T2DM (T2DM group), and a total of 41 patients were diagnosed with T2DM combined with DKD (T2DM and DKD group). Forty control participants served as a control group. All participants' body mass index (BMI), course of type 2 diabetes, patient's systolic blood pressure (SBP) and diastolic blood pressure (DBP), creatinine (Cr), urea nitrogen (BUN), fasting blood glucose (FPG), glycosylated hemoglobin (HbAlc), Fasting Serum Insulin (FINS), Insulin Resistance Index (HOMA-IR) were collected, and serum asprosin levels were detected by ELISA. The relationship between asprosin and related indicators was analyzed.

Results

The serum asprosin, Cr, FPG, HbAlc, FINS and HOMA-IR levels in the T2DM group were significantly higher than those in the control group. The serum asprosin, Cr, FPG, HbAlc, FINS and HOMA-IR levels in the T2DM and DKD group were significantly higher than those in T2DM Group and control group (P<0.01); serum asprosin levels are significantly positively correlated with Cr, FPG, HbAlc, and FINS levels (P<0.01), and there is no significant correlation with age, BMI, SBP, DBP and BUN levels Sex (P>0.05).

Conclusions

Serum asprosin levels in patients with T2DM combined with DKD are significantly increased, and are positively correlated with renal function indexes and glucose metabolism indexes.

Key words: Asprosin, Diabetic nephropathy, Type 2 diabetes, Creatinine, Insulin resistance

Yong Wu, Weiping Lin, Siyi Li, Liwen Yang, Ying Liu. Correlation study of serum asprosin levels with renal function and glucose metabolism indexes in patients with diabetic nephropathy.[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2021, 07(02): 104-107.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2021.02.007

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2021/V07/I02/104

Figures/Tables 3

References 15

[1]	HAN Q, ZHU H, CHEN X, et al. Non-genetic mechanisms of diabetic nephropathy [J]. Front Med, 2017, 11 (3): 319-332.
[2]	Choi HN, Yim JE. Plasma adropin as a potential marker predicting obesity and obesity-associated cancer in korean partients with type2 diabetes mellitus [J]. Journal of Cancer Prevention, 2018, 23(4): 191-196.
[3]	郭庆, 陈诗意, 沈静雪. 白脂素与2型糖尿病和非酒精性脂肪性肝病的关系 [J]. 沈阳医学院学报, 2020, 22(05): 480-490.
[4]	Duerrschmid C, He Y, Wang C, et al. Asprosin is a centrally acting orexigenic hormone [J]. Nat Med, 2017, 23(12): 1444-1453.
[5]	Czech MP. Insulin action and resistance in obesity and type 2 diabetes [J]. Nat Med, 2017, 23：804-814.
[6]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版) [J]. 中国实用内科杂志, 2018, 38(04): 292-344.
[7]	赛米`赛麦提, 买买提·依斯热依力, 艾克拜尔·艾力. 肥胖与2型糖尿病关系的研究进展 [J/CD].中华肥胖与代谢病电子杂志, 2020, 6(2): 130-134.
[8]	张校康, 李秉哲, 李宝新, 等. 糖尿病肾病患者血清Adropin蛋白水平变化及与肾功能和糖代谢指标的相关性分析 [J]. 微循环学杂志, 2020, 30(04): 17-20.
[9]	Jung TW, Kim HC, Kim HU, et al. Asprosin attenuates insulin signaling pathway through PKCdelta -activated ER stress and inflammation in skeletal muscle [J]. J Cell Physiol, 2019, 234(11): 20888- 20899.
[10]	Li E, Shan H, Chen L, et al. OLFR 734 mediates glucose metabolism as a receptor of asprosin[J]. Cell Metab, 2019, 30(2): 319-328.
[11]	Ko JR, Seo DY, Kim TN, et al. Aerobic exercise training decreases hepatic asprosin in diabetic rats [J]. J Clin Med, 2019, 8(5): 666.
[12]	Zhang L, Chen C, Zhou N, et al. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride [J]. Clin Chim Acta, 2019, 489: 183-188.
[13]	金童, 陈铖. 内质网应激及其在糖尿病肾病中的作用机制 [J]. 生物技术进展, 2021, 11(01): 40-46.
[14]	Wang Y, Qu H, Xiong X, et al. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and corre-lated with insulin resistance and first-phase insulin secretion [J]. Mediators Inflamm, 2018, 2018: 9471583.
[15]	李行, 邵加庆, 郑宏庭, 等. 新型脂肪因子白脂素与糖尿病的研究进展 [J]. 中国糖尿病杂志, 2020, 28(06): 476-479.

组别	n	性别（男/女）	年龄（岁）	BMI（kg/m²）	病程（年）	SBP（mmHg）	DBP（mmHg）
对照组	40	17/23	52.3±2.5	22.4±2.1	-	124.4±7.2	75.7±5.5
T2DM组	43	22/21	53.6±3.1	23.2±1.9	6.3±1.5	126.5±6.3	77.4±6.3
T2DM并DKD组	41	24/17	52.8±3.4	22.8±2.3	8.6±2.4	127.1±7.6	78.1±6.1
P值		0.352	0.146	0.227	<0.01*	0.198	0.183

组别	n	性别（男/女）	年龄（岁）	BMI（kg/m²）	病程（年）	SBP（mmHg）	DBP（mmHg）
对照组	40	17/23	52.3±2.5	22.4±2.1	-	124.4±7.2	75.7±5.5
T2DM组	43	22/21	53.6±3.1	23.2±1.9	6.3±1.5	126.5±6.3	77.4±6.3
T2DM并DKD组	41	24/17	52.8±3.4	22.8±2.3	8.6±2.4	127.1±7.6	78.1±6.1
P值		0.352	0.146	0.227	<0.01*	0.198	0.183

组别	n	asprosin（ng/ml）	Cr（μmol/L）	BUN（mmol/L）	FPG（mmol/L）	HbAlc（%）	FINS（mU/L）	HOMA-IR
对照组	40	1.17±0.25	60.4±5.3	6.07±1.22	5.3±0.4	5.0±0.5	9.3±0.5	2.1±0.2
T2DM组	43	1.75±0.46^*	67.2±5.2^*	6.21±1.43	9.7±2.1^*	6.7±0.6^*	14.4±3.1	4.8±0.7
T2DM并DKD组	41	2.21±0.34^*#	78.5±6.1^*#	6.42±1.35	10.1±2.4^*#	7.4±1.2^*#	16.2±4.2	6.2±0.3
P值		<0.01	<0.01	0.497	<0.01	<0.01	<0.01	<0.01

组别	n	asprosin（ng/ml）	Cr（μmol/L）	BUN（mmol/L）	FPG（mmol/L）	HbAlc（%）	FINS（mU/L）	HOMA-IR
对照组	40	1.17±0.25	60.4±5.3	6.07±1.22	5.3±0.4	5.0±0.5	9.3±0.5	2.1±0.2
T2DM组	43	1.75±0.46^*	67.2±5.2^*	6.21±1.43	9.7±2.1^*	6.7±0.6^*	14.4±3.1	4.8±0.7
T2DM并DKD组	41	2.21±0.34^*#	78.5±6.1^*#	6.42±1.35	10.1±2.4^*#	7.4±1.2^*#	16.2±4.2	6.2±0.3
P值		<0.01	<0.01	0.497	<0.01	<0.01	<0.01	<0.01

指标	r值	P值
年龄	-0.051	0.742
BMI	0.176	0.075
SBP	0.095	0.143
DBP	0.102	0.126
Cr	0.465	<0.01
BUN	0.047	0.783
FPG	0.662	<0.01
HbAlc	0.542	<0.01
FINS	0.652	<0.01
HOMA-IR	0.485	<0.01

Please choose a citation manager

Content to export